News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Investment Funds available for Penn Startups
Penn has three investment funds available for early stage startups affiliated with the University.
Executive Director of Bayh-Dole Coalition Explains the Current State of Bayh Dole
Joe Allen, Executive Director of the Bayh-Dole Coalition, shared insights about recent challenges to the Bayh-Dole Act,
John Swartley Appointed to Ben Franklin Technology Partners of Southeastern Pennsylvania Board of Directors
John Swartley, MBA, PhD, Chief Innovation Officer at Penn, will provide strategic oversight and guidance to support the organization’s mission.
Governor Shapiro Secures Over $1 Billion Investment from Johnson & Johnson to Build Manufacturing Facility in Montgomery County
The facility will directly support the production of medicines for cancer, immune-mediated diseases and neurological diseases.
Governor Shapiro Secures Historic $3.5 Billion Investment from Eli Lilly to Build Pharmaceutical Manufacturing Facility in Lehigh County
Lilly’s investment is the largest by a life sciences company in Pennsylvania's history.
Four Penn Medicine Studies Named Among Nation’s Top 10 Clinical Research Advances
The Clinical Research Forum’s Top 10 Clinical Research Achievement Awards honor outstanding accomplishments in clinical research.
CarboWells Wins the 2026 Y-Prize Competition
The winning idea is based on technology developed by Shu Yang, PhD.
Penn Medicine and CHOP Faculty Make the TIME100 Health List for CRISPR Gene Therapy Breakthrough
Two doctors were recognized by TIME as pioneers in healthcare for successfully treating KJ Muldoon.
Penn Received $7.8 Million from ARPA-H to Advance Lymphatic Imaging and AI-Driven Disease Detection
The project is led by Maxim Itkin, MD, Professor of Radiology at Penn Medicine and the director of Penn’s Center for Lymphatic Disorders.
T Cells Targeting Misformed Proteins to Treat Neurodegenerative and Muscular Diseases
By targeting disease-specific proteins, this antigen-specific immunotherapy aims to selectively eliminate damaged cells, potentially offering a more precise and effective treatment approach.